ERBB2 and gastric cancer: The analysis results underscore that, under current WTP threshold in China and US, the ramucirumab plus paclitaxel regimen lacks cost-effectiveness compared to continuing oxaliplatin-based chemotherapy in HER2-negative advanced GC or GEJC patients—a conclusion consistent across both the overall population and the PD-L1 CPS ≥5 population.